ADMA - ADMA Biologics gains as guidance exceeds consensus

ADMA Biologics ( NASDAQ: ADMA ), a biotech focused on plasma-derived treatments, added ~3% pre-market Tuesday after pre-announcing its Q4 2022 and full-year financials and setting its 2023 outlook ahead of Wall Street forecasts.

Based on preliminary unaudited, the company expects its total revenue for Q4 and the full year to reach ~$49 – $50M and $153 – $154M with ~89% YoY and ~90% YoY growth, compared to $43.75M and $148.88M in the consensus, respectively.

ADMA's ( ADMA ) full-year 2023 revenue is projected to reach $210M or more, indicating ~40% YoY growth ahead of the $197.43M in the consensus.

The yearly outlook assumes further market share gains to ADMA ( ADMA ) with the continued growth of the U.S. immune globulin market.

The company also anticipates first-time positive EBITDA during H2 2023 as a favorable product mix and efficiencies in the supply chain and manufacturing activities improve margins.

This year, ADMA ( ADMA ) expects to open its tenth plasma collection center and obtain the FDA nod for three more plasma collection centers.

Seeking Alpha contributor, Zach Bristow wrote on Sunday that the company's upcoming 2022 earnings release is "a key inflection point to see what's in store for investors this year."

For further details see: